Prime Medicine (PRME) Competitors $3.16 +0.09 (+2.93%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$3.24 +0.07 (+2.37%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. CRMD, NAGE, WVE, AUPH, ELVN, ABCL, PAHC, VERV, COLL, and NTLAShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include CorMedix (CRMD), Niagen Bioscience (NAGE), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors CorMedix Niagen Bioscience WAVE Life Sciences Aurinia Pharmaceuticals Enliven Therapeutics AbCellera Biologics Phibro Animal Health Verve Therapeutics Collegium Pharmaceutical Intellia Therapeutics CorMedix (NASDAQ:CRMD) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings. Do analysts recommend CRMD or PRME? CorMedix currently has a consensus price target of $17.14, indicating a potential upside of 47.28%. Prime Medicine has a consensus price target of $10.08, indicating a potential upside of 219.09%. Given Prime Medicine's higher probable upside, analysts clearly believe Prime Medicine is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more risk & volatility, CRMD or PRME? CorMedix has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Does the media favor CRMD or PRME? In the previous week, CorMedix had 18 more articles in the media than Prime Medicine. MarketBeat recorded 21 mentions for CorMedix and 3 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.97 beat CorMedix's score of 0.47 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CRMD or PRME more profitable? CorMedix has a net margin of 20.81% compared to Prime Medicine's net margin of 0.00%. CorMedix's return on equity of 22.57% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets CorMedix20.81% 22.57% 17.02% Prime Medicine N/A -107.87%-74.97% Do insiders & institutionals believe in CRMD or PRME? 34.2% of CorMedix shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 5.3% of CorMedix shares are owned by insiders. Comparatively, 22.9% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, CRMD or PRME? CorMedix has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M18.16-$17.93M$0.2252.91Prime Medicine$3.85M107.88-$198.13M-$1.61-1.96 SummaryCorMedix beats Prime Medicine on 10 of the 16 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$414.89M$202.67M$5.50B$20.64BDividend YieldN/AN/A5.38%3.74%P/E Ratio-1.54N/A27.6028.10Price / Sales107.88223.65368.8154.14Price / CashN/A22.4436.6322.31Price / Book2.315.618.054.59Net Income-$198.13M-$96.61M$3.18B$986.06M7 Day Performance30.58%-0.63%2.82%2.79%1 Month Performance139.39%-0.97%3.70%5.42%1 Year Performance-40.82%16.23%35.41%14.63% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.7656 of 5 stars$3.16+2.9%$10.08+219.1%-40.8%$414.89M$3.85M-1.54234Gap UpHigh Trading VolumeCRMDCorMedix2.6048 of 5 stars$16.56+21.7%$15.83-4.4%+181.8%$1.12B$43.47M75.2830Analyst RevisionHigh Trading VolumeNAGENiagen Bioscience1.5267 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.07B$99.60M80.24120WVEWAVE Life Sciences4.3752 of 5 stars$6.96+5.9%$20.50+194.5%+31.0%$1.07B$108.30M-8.29240AUPHAurinia Pharmaceuticals3.2625 of 5 stars$7.83+0.8%$11.50+46.9%+38.3%$1.06B$235.13M27.96300ELVNEnliven Therapeutics2.5324 of 5 stars$20.29-4.7%$39.60+95.2%-4.1%$995.61MN/A-10.5750Analyst ForecastAnalyst RevisionHigh Trading VolumeABCLAbCellera Biologics2.503 of 5 stars$3.33-2.3%$8.33+150.3%+40.4%$993.75M$23.11M-5.95500PAHCPhibro Animal Health3.6535 of 5 stars$24.46+2.4%$20.80-15.0%+63.3%$991.36M$1.02B31.361,940VERVVerve Therapeutics3.4506 of 5 stars$11.11+0.5%$14.75+32.8%+118.4%$990.35M$32.33M-5.27110High Trading VolumeCOLLCollegium Pharmaceutical4.1415 of 5 stars$29.88+0.2%$43.75+46.4%-6.1%$960.10M$664.28M24.49210NTLAIntellia Therapeutics4.7197 of 5 stars$9.23+0.3%$34.95+278.7%-53.3%$956.04M$57.88M-1.76600News Coverage Related Companies and Tools Related Companies CorMedix Alternatives Niagen Bioscience Alternatives WAVE Life Sciences Alternatives Aurinia Pharmaceuticals Alternatives Enliven Therapeutics Alternatives AbCellera Biologics Alternatives Phibro Animal Health Alternatives Verve Therapeutics Alternatives Collegium Pharmaceutical Alternatives Intellia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRME Stock Alerts